{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:00:31Z","timestamp":1785128431744,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the value of dynamic changes and trajectory fitting of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) in the prognosis of non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 244 NSCLC patients treated in our hospital from January 2019 to December 2022. CEA and CA19\u20139 levels were collected before treatment and at 14 days, 28 days, 3 months, and 6 months post-treatment. Latent class growth models were used to analyze the change trajectories of the CEA and CA19\u20139 levels. Independent prognostic factors affecting overall survival (OS) in patients with NSCLC were identified using Cox regression analysis. A Nomogram model was developed to predict survival rates, with the classification performance evaluated using calibration curves and the area under the time-dependent ROC curve (AUC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both CEA and CA19\u20139 trajectories in NSCLC patients were categorized into two distinct patterns: a continuously decreasing pattern and a decreasing-then-increasing pattern. The Results from the multivariate COX regression and nomogram indicated that advanced age, smoking, advanced TNM stage, squamous cell carcinoma, and decreased CEA or CA19\u20139 levels before reaching stable state were factors associated with reduced OS in patients with NSCLC. The AUC values of the ROC curves for the 1-, 2-, and 3-year survival rates in the training set were 0.733, 0.863, and 0.840, respectively. The AUC values for the test set were 0.769, 0.726, and 0.760, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Advanced age, smoking history, high TNM stage, squamous cell carcinoma, initial decrease followed by an increase in CEA, and initial decrease followed by an increase in CA19\u20139 are risk factors for reduced OS in patients with NSCLC. The clinical application of these factors enables the early identification of high-risk patients, facilitating early detection and intervention, and provides valuable data references for improving the prognosis of patients with NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1808730","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:24:52Z","timestamp":1785126292000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Value of serum CEA and CA19\u20139 dynamic changes and trajectory modeling in prognosis assessment for non-small cell lung cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Cardiothoracic Surgery, Air Force Hospital of the Southern War Zone of the Chinese People\u2019s Liberation Army","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyun","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Air Force Hospital of the Southern War Zone of the Chinese People\u2019s Liberation Army","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Air Force Hospital of the Southern War Zone of the Chinese People\u2019s Liberation Army","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujun","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Air Force Hospital of the Southern War Zone of the Chinese People\u2019s Liberation Army","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Outpatient, Air Force Hospital of the Southern War Zone of the Chinese People\u2019s Liberation Army","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The First Affiliated Hospital of Changsha Medical University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Air Force Hospital of the Southern War Zone of the Chinese People\u2019s Liberation Army","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a037812","article-title":"Molecular pathology of lung cancer","volume":"12","author":"Saller","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: Management of non-small-cell lung cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/bs.acc.2022.09.004","article-title":"Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers","volume":"112","author":"Kurose","year":"2023","journal-title":"Adv Clin Chem"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.3233\/tub-220034","article-title":"Clinical perspectives on serum tumor marker use in predicting prognosis and treatment response in advanced non-small cell lung cancer","volume":"46","author":"Buma","year":"2024","journal-title":"Tumour Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s43556-024-00181-3","article-title":"Carcinoembryonic antigen potentiates non-small cell lung cancer progression via PKA-PGC-1\u0251 axis","volume":"5","author":"Lei","year":"2024","journal-title":"Mol BioMed"},{"key":"B8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s12094-023-03339-7","article-title":"Correlation between carcinoembryonic antigen (CEA) expression and EGFR mutations in non-small-cell lung cancer: a meta-analysis","volume":"26","author":"Gan","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.3390\/cancers14205064","article-title":"The indicative value of serum tumor markers for metastasis and stage of non-small cell lung cancer","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28566","article-title":"Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management","volume":"15","author":"Strum","year":"2024","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13000-023-01349-1","article-title":"Molecular profiling and prognostic biomarkers in Chinese non-small cell lung cancer cohort","volume":"18","author":"Shen","year":"2023","journal-title":"Diagn Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0036","article-title":"NCCN guidelines\u00ae Insights: lung cancer screening, version 1.2022","volume":"20","author":"Wood","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20210207-00377","article-title":"Chinese medical association oncology branch clinical practice guidelines for lung cancer diagnosis and treatment (2021 edition)","volume":"101","year":"2021","journal-title":"Natl Med J China"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003268","article-title":"Global burden of lung cancer in 2022 and projected burden in 2050","volume":"137","author":"Guo","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7754\/clin.lab.2022.220728","article-title":"Diagnostic value of seven autoantibodies combined with CEA and CA199 in non-small cell lung cancer","volume":"69","author":"Xie","year":"2023","journal-title":"Clin Lab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/00368504251352375","article-title":"Preoperative lipid levels and prognosis in non-small cell lung cancer: A retrospective age-stratified study","volume":"108","author":"Liu","year":"2025","journal-title":"Sci Prog"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107925","article-title":"Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis","volume":"195","author":"Ding","year":"2024","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111901","article-title":"Prognostic impact of age in advanced non-small cell lung cancer patients undergoing first-line checkpoint inhibitor immunotherapy and chemotherapy treatment","volume":"132","author":"Huang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03844-8","article-title":"Non-small cell lung cancer in ever-smokers vs never-smokers","volume":"23","author":"Burt","year":"2025","journal-title":"BMC Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.jtcvs.2020.03.175","article-title":"Non-small cell lung cancer in never- and ever-smokers: Is it the same disease","volume":"161","author":"Tang","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.02.011","article-title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for revision of the TNM stage groups in the forthcoming (Ninth) edition of the TNM classification for lung cancer","volume":"19","author":"Rami-Porta","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108634","article-title":"MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review","volume":"206","author":"Shi","year":"2025","journal-title":"Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2025.10.001","article-title":"Squamous non-small cell lung cancer: Current and emerging treatment options","author":"Paik","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccell.2023.12.004","article-title":"A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1627122","article-title":"Trajectories of perioperative serum CEA and non-small cell lung cancer prognosis: a retrospective longitudinal cohort study","volume":"15","author":"Ma","year":"2025","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.21037\/tlcr-20-805","article-title":"Evolving target volume concepts in locally advanced non-small cell lung cancer","volume":"10","author":"Nestle","year":"2021","journal-title":"Transl Lung Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1808730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:24:53Z","timestamp":1785126293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1808730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":27,"alternative-id":["10.3389\/fonc.2026.1808730"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1808730","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1808730"}}